Halozyme Therapeutics (MEX:HALO) Cyclically Adjusted FCF per Share: MXN28.05 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:HALO Halozyme Therapeutics Inc MEX:HALO
87 GF Score
Price MXN1,327.00
GF Value MXN1,635.14
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Cyclically Adjusted FCF per Share?

Halozyme Therapeutics MEX:HALO 87 Cyclically Adjusted FCF per Share is MXN28.05 as of Mar. 2026. GuruFocus rates MEX:HALO with a GF Score™ of 87/100 and a GF Value™ of MXN1,635.14 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Halozyme Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was MXN25.879. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN28.05 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Halozyme Therapeutics's average Cyclically Adjusted FCF Growth Rate was 33.90% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 83.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Halozyme Therapeutics was 83.10% per year. The lowest was -12.90% per year. And the median was 2.90% per year.

As of today (2026-07-19), Halozyme Therapeutics's current stock price is MXN1327.00. Halozyme Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was MXN28.05. Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF of today is 47.31.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Halozyme Therapeutics was 1610.00. The lowest was 41.53. And the median was 71.02.


Halozyme Therapeutics  (MEX:HALO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=1327.00/28.05
=47.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Halozyme Therapeutics was 1610.00. The lowest was 41.53. And the median was 71.02.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Halozyme Therapeutics Cyclically Adjusted FCF per Share Related Terms


Halozyme Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Cyclically Adjusted FCF per Share Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.58 2.63 10.30 14.22 24.59

Halozyme Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.26 24.08 21.42 24.59 28.05

MEX:HALO vs KYMR, IBRX, PRAX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


MEX:HALO
87GF Score
Halozyme Therapeutics Inc MEX:HALO
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Halozyme Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=25.879/330.2130*330.2130
=25.879

Current CPI (Mar. 2026) = 330.2130.

Halozyme Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -2.025 241.018 -2.774
201609 -1.384 241.428 -1.893
201612 -2.608 241.432 -3.567
201703 -3.302 243.801 -4.472
201706 -2.323 244.955 -3.132
201709 2.546 246.819 3.406
201712 19.642 246.524 26.310
201803 -2.931 249.554 -3.878
201806 -2.638 251.989 -3.457
201809 -2.503 252.439 -3.274
201812 1.006 251.233 1.322
201903 -0.704 254.202 -0.915
201906 -3.455 256.143 -4.454
201909 -4.146 256.759 -5.332
201912 -3.647 256.974 -4.686
202003 -0.847 258.115 -1.084
202006 0.465 257.797 0.596
202009 0.919 260.280 1.166
202012 6.709 260.474 8.505
202103 7.985 264.877 9.955
202106 4.902 271.696 5.958
202109 16.995 274.310 20.458
202112 11.714 278.802 13.874
202203 6.667 287.504 7.657
202206 5.553 296.311 6.188
202209 9.904 296.808 11.019
202212 11.206 296.797 12.468
202303 9.880 301.836 10.809
202306 8.789 305.109 9.512
202309 16.819 307.789 18.044
202312 12.917 306.746 13.905
202403 16.209 312.332 17.137
202406 7.544 314.175 7.929
202409 17.228 315.301 18.043
202412 28.334 315.605 29.645
202503 24.760 319.799 25.566
202506 14.885 322.561 15.238
202509 26.327 324.800 26.766
202512 -10.333 324.054 -10.529
202603 25.879 330.213 25.879

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN28.05 mean?
Halozyme Therapeutics (MEX:HALO) has a Cyclically Adjusted FCF per Share of MXN28.05 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Cyclically Adjusted FCF per Share too high?
Halozyme Therapeutics' current Cyclically Adjusted FCF per Share is MXN28.05. Overall, Halozyme Therapeutics has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Cyclically Adjusted FCF per Share compare to KYMR and IBRX?
Halozyme Therapeutics' Cyclically Adjusted FCF per Share of MXN28.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Cyclically Adjusted FCF per Share is MXN28.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (MEX:HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,635.14, compared to a current price of MXN1,327.00 — trading 18.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN28.05. Halozyme Therapeutics' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Halozyme Therapeutics (MEX:HALO), the current Cyclically Adjusted FCF per Share is MXN28.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (MEX:HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of MXN1,327.00 is trading 18.8% below its estimated GF Value™ of MXN1,635.14. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for MEX:HALO:

  • Cyclically Adjusted FCF per Share: MXN28.05
  • GF Value™: MXN1,635.14 vs. price of MXN1,327.00 (18.8% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the MEX:HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
87GF Score

Get the complete analysis for MEX:HALO

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,327.00
Price
MXN1,635.14
GF Value